The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021

What is already known about this topic? On October 29, 2021, the Food and Drug Administration granted Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine for children aged 5–11 years. What is added by this report? On November 2, 2021, after a systematic review of available data, the...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2021-11, Vol.70 (45), p.1579-1583
Main Authors: Woodworth, Kate R, Moulia, Danielle, Collins, Jennifer P, Hadler, Stephen C, Jones, Jefferson M, Reddy, Sujan C, Chamberland, Mary, Campos-Outcalt, Doug, Morgan, Rebecca L, Brooks, Oliver, Talbot, H. Keipp, Lee, Grace M, Bell, Beth P, Daley, Matthew F, Mbaeyi, Sarah, Dooling, Kathleen, Oliver, Sara E
Format: Article
Language:English
Subjects:
Age groups
Children
Clinical trials
Coronaviruses
COVID-19
COVID-19 vaccines
Disease transmission
Drug approval
Full Report
Health surveillance
Hospitalization
Immunization
Infections
Influenza
Medical laboratories
Multisystem inflammatory syndrome in children
Pandemics
Pharmaceutical industry
Prevention
Public health
Severe acute respiratory syndrome coronavirus 2
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:What is already known about this topic? On October 29, 2021, the Food and Drug Administration granted Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine for children aged 5–11 years. What is added by this report? On November 2, 2021, after a systematic review of available data, the Advisory Committee on Immunization Practices made an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5–11 years in the United States for prevention of COVID-19. What are the implications for public health practice? The Pfizer-BioNTech COVID-19 vaccine has high efficacy (>90%) against COVID-19 in children aged 5–11 years, and benefits outweigh risks for vaccination. Vaccination is important to protect children against COVID-19 and reduce community transmission of SARS-CoV-2.
ISSN:0149-2195
1545-861X
DOI:10.15585/MMWR.MM7045E1